The primary endpoint was progression-free survival (PFS; nivolumab/ipilimumab vs chemotherapy and nivolumab/ipilimumab vs nivolumab monotherapy). Findings showed the risk of disease progression or ...

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...

Nivolumab is a monoclonal antibody and a PD-1 inhibitor (programmed death receptor inhibitor) which is prescribed for cancer treatment. The therapeutic efficacy of Bacillus calmette-guerin ...